Ignite Creation Date:
2025-12-24 @ 8:03 PM
Ignite Modification Date:
2025-12-28 @ 9:09 PM
Study NCT ID:
NCT05131204
Status:
TERMINATED
Last Update Posted:
2025-04-08
First Post:
2021-11-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
Sponsor:
Regeneron Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-10-06
Start Date Type:
ACTUAL
Primary Completion Date:
2023-07-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-07-12
Completion Date Type:
ACTUAL
First Submit Date:
2021-11-12
First Submit QC Date:
None
Study First Post Date:
2021-11-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-07-09
Results First Submit QC Date:
None
Results First Post Date:
2024-09-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-03
Last Update Post Date:
2025-04-08
Last Update Post Date Type:
ACTUAL